Comparative study of the effect of *Thymus daenensis* gel 5% and diclofenac in patients with knee osteoarthritis

Morteza Dehghan¹, Shirin Asgharian², Elena Khalesi¹, Ali Ahmadi³, Zahra Lorigooini²,*

¹Clinical Research Development Unit, Kashani Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran.  
²Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran  
³Modeling in Health Research Center, Department of Epidemiology and Biostatistics, School of Public Health, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Received 15th of December, 2018    Accepted 18th of March, 2019

© Author(s) 2019. This article is published with open access by China Medical University

1. Introduction

Osteoarthritis (OA) is a syndrome characterized by joint pain and reduced performance and efficiency in patient [1]. Osteoarthritis is one of the most common musculoskeletal disorders. According to several reports, the incidence of knee osteoarthritis has been higher than the incidence of hip osteoarthritis [2-4]. According to the World Health Organization report, 18% of women and 6.9% of men aged over 60 suffer from osteoarthritis [5]. Osteoarthritis treatment is aimed to reduce pain, swelling and disability resulting from inflammation and an increased quality of life, since there is no decisive cure for it [6]. Some of the solutions used for the treatment of this disease include lifestyle changes, medicinal treatments, physical treatments, and finally surgery interventions [7-9]. In this regard, medicinal treatments including NSAIDs are the main choice for osteoarthritis of the knee [10]. However, adverse side effects of medications [11, 12] as well as the likelihood of other diseases cause problems in patients especially in the older patients [13, 14]. Studies have indicated increased tendency of OA patients to use complementary and alternative treatments [15, 16]. These studies show that complementary therapies have wide applications for the treatment of chronic diseases in Iran [17, 18]. One of the complementary therapies used in OA is using herbal medicines. *Thymus daenensis* is one of the effective plants for treatment of osteoarthritis in traditional medicine. *Thymus daenensis* fresh leaves and stems have a pleasant smell that results from a combination of compounds in oils and extracts of this plant. In vegetative organs of thyme, a compound such as **ABSTRACT**

Background: Osteoarthritis is a syndrome characterized by joint pain and reduced performance and efficiency in patient. *Thymus daenensis* has been used since old times for the treatment of bone and joint deformities and pain in traditional medicine.  
Purpose: This study was conducted to examine traditional usages and pharmacological features of *T. daenensis* with respect to the effect of the plant in patients with osteoarthritis.  
Methods: 120 patients with osteoarthritis were divided into 3 groups. Patients in each group were treated by 5% *Thymus daenensis* gel, 1% diclofenac gel, or placebo for 6 weeks, along with oral celecoxib capsules. Patients were assessed in different intervals, based on the VAS score for assessment of pain in the joint and different dimensions of WOMAC questionnaire.  
Results: Pain level (*P* < 0.005), stiffness during the day (*P* < 0.05), morning stiffness (*P* < 0.05) and physical performance (*P* < 0.05) were significantly different among the groups.  
Conclusions: *Thymus daenensis* gel improves the symptoms in patients equal and without significant difference than diclofenac group. It can be argued that its use can produce a satisfactory effect on patients with osteoarthritis due to its low cost, easy access, the plant's natively occurring in Iran.
phenols, tannins, flavonoids, saponins, and bitter substances are found [19-21]. The leaves and flowers of this plant are used as antitussive, antispasmodic and anti-flatulence and to treat colds [22, 23]. *Thymus daenensis* has several properties such as anti-bacterial and antifungal [24-33], and antioxidants [34-42] properties; it also reduces the fat content [43]. It also has anti-inflammatory properties [44-46] and strengthens the immune system of the body [47], and it inhibits tyrosinase [48]. According to the culture governing the country in higher acceptance of medicinal plants and higher acceptance of them by patients and lower side effects of these drugs, this study was performed to investigate the impacts of topical *Thymus daenensis* gel in treating and controlling symptoms of osteoarthritis.

2. Method

This study has three intervention groups (diclofenac group, herbal gel group and placebo group) with the double-blind clinical trial.

2.1. Ethical considerations

The study design is in compliance with the ethical principles of Helsinki Declaration. This study protocol was approved at the Behavioral Sciences Ethics Committee of Shahrekord University of Medical Sciences (ethics code IR.SKUMS.REC.1395.54) and then in the Iranian clinical trial registration center with code IRCT2016112231025N1. Informed consent form was taken from patients participating in the study.

2.2. Plant material and extraction method

*Thymus daenensis* aerial parts were collected from mountainous areas of the province in the spring of 2016. Collected Plants were identified by Dr. Shirmandi and a herbarium voucher (no. 248) was deposited at the Herbarium of the Medical Plants Research Center of Shahrekord University of Medical Sciences. The powdered plant was extracted by maceration method with Ethanol 70% for 48 h. The obtained extract was passed through filter paper. To remove solvent, the extract was concentrated by rotary evaporator at 37°C and lyophilized by freeze dryer. Then, *Thymus daenensis* gel 5% was formulated in gel base from poly Carbopol-940 as U.S. Pharmacopeia. Diclofenac Gel 1% of Emad-Darman Pars Company and placebo were filled in same aluminum tubes like *Thymus daenensis* gel.

2.3. Standardization of topical gel

The total phenolic content of aqueous *Thymus daenensis* extract was measured using Folin-Ciocalteu. To this end, 1 mg/ml crude extract reached a volume of 3 ml by addition of distilled water and then combined with 0.5 ml Folin-ciocalteu reagent for 10 minutes. Next, 4 ml sodium carbonate was added to the resulting mixture. The obtained extract was stored in dark for the half for an hour and the optical absorbance was read at 765nm wavelength. The total phenolic content was measured by using calibration curve, and the results were expressed as the total phenolic content (mg of Gallic acid equivalent/g dried extract) [49]. The total flavonoid content Flavonoids were measured according to Liang et al. method with some modifications. In short, 5.0 ml of each extract solution (0.01 g per 10 ml of methanol at 60°C) was mixed with 0.5 ml of 2% aluminum chloride and 3 ml of 5% potassium acetate. After 40 minutes, the absorption of samples was read against distilled water (blank) at a wavelength 415 nm. While carrying out the experiment, various concentrations of Rutin were prepared. Absorption of samples was compared with a standard curve and total flavonoid content of each extract was stated as mg of Rutin equivalent/g dried extract [50].

2.4. Exclusion criteria

Simultaneous severe diseases such as metabolic and gastrointestinal diseases, fluctuation in the dose of the drug during the study, the presence of severe infection, allergy to drugs, pregnancy, lactation, liver abnormal performance tests, history of fracture or surgery on the knee, rheumatoid arthritis and seronegative and seropositive arthropathies, intra-articular injection during 6 weeks, simultaneous use of any type of tranquilizer that caused disturbance in the result were exclusion criteria of study. In addition, patients who had no willingness in the study were excluded from the study.

2.5. Inclusion criteria

Men and women with knee osteoarthritis, diagnosed by an orthopedic according to diagnostic criteria, aged 45-75 years who had referred to the Orthopaedic Clinic of Shahrkord University of Medical Sciences at least 3 months before the start of the study, were included in the study. They signed an informed consent to participate in the study.

2.6. Intervention

The first group received 200 mg capsules celecoxib orally and topical gel placebo, the second group received 200 mg capsules celecoxib orally on a daily basis and topical 5% thyme gel and the third group received 200 mg capsules celecoxib orally and topical diclofenac 1% gel 3 times daily for 6 weeks. Patients were instructed that the gel should cover the entire surface of the knee. Topical gel dose for each 5 square centimeters of skin was knuckle. To ensure lack of any additional intervention, patients were asked to not massage the knee.

2.7. Effectiveness evaluation

Patient evaluation was performed by means of the Visual Analogue Scale (VAS) to score knee pain at baseline and on the first and third days and first, third, and sixth weeks following the intervention. Besides that, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) that is a general and valid instrument to examine OA was used as another measurement tool. This questionnaire examines three dimensions: pain dimension (scored between 0 representing no pain and 4 representing severe pain), physical performance (scored between 0 representing no problem and 4 representing severe problem) and stiffness (scored between 0 representing without stiffness and 4 representing severe stiffness). The scores of the dimensions were summed and the mean value was calculated. This questionnaire was evaluated before treatment and during the first, third days and the first, third and sixth weeks after the intervention [21].

2.8. Safety evaluation

All patients were asked to report incidence of allergies or adverse
Variance (ANOVA) was used to compare quantitative variables. Repeated measurement and One-way analysis of variance were examined. Performance and improvement rate stiffness of knee in studied groups were compared. Morning stiffness of knee joint, improvement in physical performance, and pain level were applied. Difference in pretest and post-test scores between the control and intervention groups were compared. Pain level, as well as potential adverse reactions, were investigated by asking the participants open-ended questions.

2.9. Sampling, randomization and blinding

Non-probability convenient sampling was used to select samples. To this end, the participants were selected from the patients admitted to the clinic. To enroll minimum number of people by taking dropouts into account, 120 people were enrolled in this study who were assigned to three groups of 40 each. Group 1 received placebo gel, group 2 received Thymus daenensis extract gel, and group 3 received gel containing diclofenac. To collect data, using convenient sampling method, the 120 participants were assigned to tube A, tube B, and tube C (each containing 40) and by using random sampling method; the patient was asked to select one of the Tube A, B, and C. Then, the intervention was performed. Researchers, patients and statistical analysts were blind to the content of three types of tubes.

2.10. Statistical Analysis

The sample size was obtained 35 people considering 95% confidence interval, and test power of 90 percent and study power of 85 percent. Considering drop out, 120 were included in the study. Data were analyzed using STATA software. For data analysis, inferential and descriptive statistics and duplicate data analysis were applied. Difference in pretest and post-test scores between the control and intervention groups were compared. Pain level, morning stiffness of knee joint, improvement in physical performance and improvement rate stiffness of knee in studied groups were examined. Repeated measurement and One-way analysis of variance (ANOVA) was used to compare quantitative variables between the three groups. Chi-square was used to compare qualitative variables. Bonferroni test was used for multiple comparisons.

3. Results

3.1. Standardization of Thymus daenensis gel

The total phenolic content of 1 g of Thymus daenensis gel was obtained 5.56 ± 0.98 mg Gallic acid equivalent. Total flavonoid content of 1 g of prepared gel was obtained 0.98 ± 0.06 mg Rutin equivalent.

3.2. The baseline characteristics of the study

The process of registration of patients was conducted from June to August 2016. A total of 120 registered patients were divided into three groups placebo, diclofenac gel, and herbal gel in a random manner as presented Flow Diagrams (Fig. 1). The average age of the patients was 62.75 ± 8.67 in the range of 45-75 years, and it was 62.6 ±9.04, 63.83 ± 9.12, and 61.82 ± 7.92 in the placebo, herbal gel, and diclofenac groups, respectively. Out of all patients studied, 51 (43%) were male and 69 people (57%) were female. Regarding age and gender, no significant difference was observed between the groups (p = 0.587).

3.3. Clinical responses

Pain at six intervals had overall reduction both in herbal gel group and diclofenac group. On the day before the intervention and the first day after the intervention, significant difference was not found among three groups with respect to pain reduction (14.65 ± 0.77 vs. 13.44 ± 0.72, p = 0.628) and pain reduction was not significant, but since the third day, knee pain rate was significantly different between diclofenac and placebo, and between thyme and placebo since the first week (8.05 ± 0.68 vs. 12.35 ± 0.79, 9.02 ± 0.67 vs. 12.35 ± 0.79, p <0.001) and pain in the diclofenac and thyme groups reduced since that time compared to the placebo group. No significant difference was observed between diclofenac and thyme groups with respect to reduced pain up to the third week after the intervention (6.22 ± 0.62 vs. 7.52 ± 0.73, p = 0.796), but in the sixth week, a significant difference was observed between two groups (3.57 ± 0.41 vs. 6.02 ± 3.87, p = 0.02) and rate of reduction in pain was more in diclofenac group (Table 1, Fig. 2). The pain in the right knee since the third day had a significant difference between diclofenac and placebo groups and between placebo and thyme groups since the first week and the reduced pain was observed. In addition, up to the third week, not significant difference was observed between diclofenac and Thymus daenensis groups (1.25 ± 0.13 vs. 1.58 ± 0.13, p = 0.669), but in the sixth week, a significant difference was observed between the two groups (0.67 ± 0.09 vs. 1.25 ± 0.13, p = 0.01) that this reduction was more in the diclofenac group (Table 2, Fig. 3).

The pain in the left knee since the third day had a significant difference between diclofenac and placebo groups and between placebo and thyme groups since the first week and the reduced pain was observed. Besides that, up to the third week, no significant difference was observed between diclofenac and Thymus daenensis groups (1 ± 0.13 vs. 1.45 ± 0.12, p = 0.587), but in the sixth week, a significant difference was noted between the two groups (± 0.09 vs. 1.1 ± 0.12, p = 0.04) that this reduction was.
more in the diclofenac group (Table 3, Fig. 4). Morning stiffness rate declined both in herbal gel and diclofenac groups. The morning stiffness had no significant difference among the three groups before the intervention and the first day after the intervention (3.02

Table 1 − Comparison of knee osteoarthritis patients with respect to knee pain in the 3 groups and during 6 follow-up intervals.

| Time                        | Total       | A            | B            | C            | P value |
|-----------------------------|-------------|--------------|--------------|--------------|---------|
| Before starting treatment   | 14.65 ± 0.77| 14.05 ± 0.75 | 15.05 ± 0.77 | 14.85 ± 0.80 | 0.628   |
| First day after treatment   | 13.44 ± 0.72| 13.7 ± 0.73  | 13.5 ± 0.74  | 13.07 ± 0.69 | 0.8     |
| Third day after treatment   | 11.88 ± 0.74| 13.3 ± 0.77  | 11.42 ± 0.72 | 10.92 ± 0.68 | 0.05*   |
| First week after treatment  | 9.8 ± 0.77   | 12.35 ± 0.79 | 9.02 ± 0.67  | 8.05 ± 0.68  | 0.000*  |
| Third week after treatment  | 8.21 ± 0.77  | 10.9 ± 0.84  | 7.52 ± 0.73  | 6.22 ± 0.62  | 0.000*  |
| Sixth week after treatment  | 6.65 ± 0.77  | 10.35 ± 0.82 | 6.02 ± 0.61  | 3.57 ± 0.41  | 0.000*  |

A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.

Table 2 − Comparison of knee osteoarthritis patients with respect to right knee pain in the 3 groups and during 6 follow-up intervals.

| Time                        | Total       | A            | B            | C            | P value |
|-----------------------------|-------------|--------------|--------------|--------------|---------|
| Before starting treatment   | 14.65 ± 0.77| 14.05 ± 0.75 | 15.05 ± 0.77 | 14.85 ± 0.80 | 0.628   |
| First day after treatment   | 13.44 ± 0.72| 13.7 ± 0.73  | 13.5 ± 0.74  | 13.07 ± 0.69 | 0.8     |
| Third day after treatment   | 11.88 ± 0.74| 13.3 ± 0.77  | 11.42 ± 0.72 | 10.92 ± 0.68 | 0.05*   |
| First week after treatment  | 9.8 ± 0.77   | 12.35 ± 0.79 | 9.02 ± 0.67  | 8.05 ± 0.68  | 0.000*  |
| Third week after treatment  | 8.21 ± 0.77  | 10.9 ± 0.84  | 7.52 ± 0.73  | 6.22 ± 0.62  | 0.000*  |
| Sixth week after treatment  | 6.65 ± 0.77  | 10.35 ± 0.82 | 6.02 ± 0.61  | 3.57 ± 0.41  | 0.000*  |

A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.

Fig. 2 - Comparison of knee osteoarthritis patients with respect to knee pain in the 3 groups and during 6 follow-up intervals. A: Placebo, B: Thymus daenensis group, C: Diclofenac group.

Fig. 3 - Comparison of knee osteoarthritis patients with respect to right knee pain in the 3 groups and during 6 follow-up intervals. A: Placebo, B: Thymus daenensis group, C: Diclofenac group.
Table 3 – Comparison of knee osteoarthritis patients with respect to left knee pain in the 3 groups during 6 intervals of follow-up.

|                          | Mean ± SE |  |  |  |
|-------------------------|-----------|---|---|---|
|                          | A         | B | C |  |
| Before starting treatment | 2.62 ± 0.17 | 2.9 ± 0.16 | 2.85 ± 0.15 | 0.424 |
| First day after treatment | 2.68 ± 0.17 | 2.55 ± 0.15 | 2.53 ± 0.12 | 0.754 |
| Third day after treatment | 2.55 ± 0.17 | 2.23 ± 0.13 | 1.97 ± 0.15 | 0.025* |
| First week after treatment | 2.45 ± 0.17 | 1.7 ± 0.13 | 1.58 ± 0.12 | 0.000* |
| Third week after treatment | 2.13 ± 0.18 | 1.45 ± 0.12 | 1 ± 0.13 | 0.000* |
| Sixth week after treatment | 2.03 ± 0.18 | 1.1 ± 0.12 | ± 0.09 | 0.000* |

A: Placebo, B: *Thymus daenensis* group, C: Diclofenac group *p < 0.05.

![Graph](image-url)

Fig. 4 - Comparison of knee osteoarthritis patients with respect to left knee pain in the 3 groups during 6 intervals of follow-up. A: placebo group, B: *Thymus daenensis* group, C: diclofenac group.

... ± 0.14 vs. 2.83 ± 0.14, p = 0.903), but with reduction in morning stiffness, since the third day, significant difference was observed between diclofenac and placebo groups and between thyme and placebo groups since the first week (1.85 ± 0.15 vs. 2.45 ± 0.18, 1.97 ± 0.13 vs. 2.45 ± 0.18, p < 0.01). In addition, no significant difference was observed between diclofenac and *Thymus daenensis* groups up to the third week after intervention (1.28 ± 0.013 vs. 1.6 ± 0.13, p = 0.822), but in the sixth week, the two groups also had significant differences (0.75 ± 0.09 vs. 1.3 ± 0.13, p = 0.01) and the reduction of morning stiffness in the diclofenac group was higher (Table 4, Fig. 5).

Regarding daily stiffness rate, significant difference was not found among three groups before intervention and first day after intervention (3.01 ± 0.15 vs. 2.81 ± 0.14, p > 0.05), but since the third day, significant difference was noted between diclofenac and placebo groups (2.22 ± 0.14 vs. 2.75 ± 0.16, p < 0.01), and since the first week, significant difference was observed between two thyme and placebo groups (1.93 ± 0.13 vs. 2.45 ± 0.18, p < 0.01). In these groups, pain reduction rate in diclofenac and herbal gel groups was more than the placebo group. In addition, no significant difference was observed between diclofenac and *Thymus daenensis* groups up to the third week after intervention (1.28 ± 0.13 vs. 1.55 ± 0.13, p > 0.05). However, daily stiffness reduction in the diclofenac group was higher in sixth week (0.75 ± 0.09, p < 0.02) (Table 5, Fig. 6). Both in the herbal gel group and diclofenac group, physical performance improved. Regarding physical performance in one day before the intervention and the first day after the intervention, significant difference was not found among the three groups (51.94 ± 2.63 vs. 47.71 ± 15.45, p > 0.05), but since the third day, significant difference was noted between diclofenac and placebo groups (38.67 ± 2.36 vs. 47 ± 2.56, p < 0.05) and between thyme and placebo group since the first week (32.17 ± 2.24 vs. 44.02 ± 2.78, p < 0.05) and physical performance improvement was seen in the group receiving diclofenac and the group received herbal gel. No significant difference was observed between two diclofenac and thyme groups with respect to physical performance index up to end of the intervention (12.85 ± 1.46 vs. 20.85 ± 2.24, p > 0.05) and in both groups, physical performance improvement was equal (Table 6, Fig. 7).

The knee pain rate based on VAS criterion had no significant difference before intervention and first day after the intervention (7.67 ± 0.33 vs. 7.04 ± 0.31, p > 0.05), but a significant difference was noted between placebo and diclofenac groups since the third day (7.18 ± 0.33 vs. 5.72 ± 0.28, p < 0.05) and between placebo and thyme groups since first week (6.85 ± 0.34 vs. 5.45 ± 0.31, p < 0.05) and a reduction in pain was observed. In addition, two groups of diclofenac and *Thymus daenensis* had no significant difference up to a third week (3.9 ± 0.25 vs. 4.75 ± 0.34, p > 0.05), but since the sixth week, the difference was significant between the groups (2.78 ± 0.25 vs. 4.1 ± 0.33, p < 0.05) and pain reduction in the diclofenac group was higher (Table 7, Fig. 8).

Comparison Means and 95% Confidence Intervals (CIs) of main outcomes in osteoarthritis patients before and after treatment was presented in Table 8.

### 3.4. Short term tolerance and safety

In the diclofenac group, no topical or systematic adverse effects were reported. In addition, thyme gel was accepted well by patients and no side effects or adverse physical effect was seen in follow-ups.
4. Discussion

This study examines the effect of *Thymus daenensis* extract gel on knee pain and performance of patients with osteoarthritis. Our study showed that knee pain of patients in the group consuming the *Thymus daenensis* gel significantly decreased so that knee pain reduction in thyme group was equal and without significant

**Table 4** – Comparison of knee osteoarthritis patients with respect to morning stiffness in the 3 groups during 6 intervals of follow-up.

|                      | Mean ± SE |     |     |     |     |     |
|----------------------|-----------|-----|-----|-----|-----|-----|
|                      | A         | B   | C   |     |     |     |
| Before starting treatment | 2.88 ± 0.15 | 3.07 ± 0.13 | 3.12 ± 0.16 | 0.449 |
| First day after treatment   | 2.83 ± 0.14 | 2.83 ± 0.14 | 2.85 ± 0.15 | 0.99  |
| Third day after treatment    | 2.75 ± 0.16 | 2.38 ± 0.13 | 2.22 ± 0.14 | 0.013*|
| First week after treatment   | 2.45 ± 0.18 | 1.97 ± 0.13 | 1.85 ± 0.15 | 0.019*|
| Third week after treatment    | 2.15 ± 0.18 | 1.6 ± 0.13  | 1.28 ± 0.13  | 0.000*|
| Sixth week after treatment   | 2.07 ± 0.17 | 1.3 ± 0.13  | 0.75 ± 0.09  | 0.000*|

A: Placebo, B: *Thymus daenensis* group, C: Diclofenac group *P < 0.05.

**Table 5** – Comparison of knee osteoarthritis patients with respect to daily stiffness rate in the 3 groups during 6 intervals of follow-up.

|                      | Mean ± SE |     |     |     |     |     |
|----------------------|-----------|-----|-----|-----|-----|-----|
|                      | A         | B   | C   |     |     |     |
| Before starting treatment | 2.88 ± 0.15 | 3.03 ± 0.14 | 3.12 ± 0.16 | 0.492 |
| First day after treatment   | 2.83 ± 0.14 | 2.77 ± 0.15 | 2.85 ± 0.15 | 0.934 |
| Third day after treatment    | 2.75 ± 0.16 | 2.32 ± 0.13 | 2.22 ± 0.14 | 0.027*|
| First week after treatment   | 2.45 ± 0.18 | 1.93 ± 0.13 | 2.85 ± 0.15 | 0.014*|
| Third week after treatment    | 2.15 ± 0.18 | 1.55 ± 0.13 | 1.28 ± 0.13 | 0.000*|
| Sixth week after treatment   | 2.1 ± 0.17  | 1.25 ± 0.12 | 0.75 ± 0.09  | 0.000*|

A: Placebo, B: *Thymus daenensis* group, C: Diclofenac group *P < 0.05.

Fig. 5 - Comparison of knee osteoarthritis patients with respect to morning stiffness in the 3 groups during 6 intervals of follow-up. A: Placebo group, B: *Thymus daenensis* group, C: Diclofenac group.

Fig. 6 - Comparison of knee osteoarthritis patients with respect to daily stiffness rate in the 3 groups during 6 intervals of follow-up. A: Placebo group, B: *Thymus daenensis* group, C: Diclofenac group.
Table 6 – Comparison of knee osteoarthritis patients with respect to physical performance in the 3 groups during 6 intervals of follow-up.

|                          | Mean ± SE       |                      |                      |                      | P value |
|--------------------------|-----------------|----------------------|----------------------|----------------------|---------|
|                          | Total A B C     |                      |                      |                      |         |
| Before starting treatment| 51.94 ± 2.63    | 49.57 ± 2.56         | 53.47 ± 2.54         | 53.12 ± 2.80         | 0.514   |
| First day after treatment| 47.71 ± 2.44    | 48.67 ± 2.47         | 47.72 ± 2.38         | 47.22 ± 2.55         | 0.915   |
| Third day after treatment| 41.82 ± 2.47    | 47.02 ± 2.56         | 40.27 ± 2.32         | 38.67 ± 2.36         | 0.038*  |
| First week after treatment| 35.17 ± 2.72   | 44.02 ± 2.78         | 32.17 ± 2.24         | 29.87 ± 2.56         | 0.000*  |
| Third week after treatment| 29.43 ± 2.73   | 39.42 ± 2.96         | 26.82 ± 2.24         | 22.55 ± 2.22         | 0.000*  |
| Sixth week after treatment| 23.33 ± 2.72   | 37.66 ± 2.92         | 20.85 ± 2.24         | 12.58 ± 1.46         | 0.000*  |

A: Placebo, B: *Thymus daenensis* group, C: Diclofenac group *P < 0.05.

Table 7 – Comparison of knee osteoarthritis patients with respect to pain rate in the 3 groups during 6 intervals of follow-up based on VAS criterion.

|                          | Mean ± SE       |                      |                      |                      | P value |
|--------------------------|-----------------|----------------------|----------------------|----------------------|---------|
|                          | Total A B C     |                      |                      |                      |         |
| Before starting treatment| 7.67 ± 0.33     | 7.45 ± 0.32          | 7.88 ± 0.34          | 7.65 ± 0.33          | 0.502   |
| First day after treatment| 7.04 ± 0.31     | 7.35 ± 0.32          | 7 ± 0.32             | 6.75 ± 0.30          | 0.317   |
| Third day after treatment| 6.41 ± 0.33     | 7.18 ± 0.33          | 6.38 ± 0.33          | 5.72 ± 0.28          | 0.006*  |
| First week after treatment| 5.67 ± 0.34    | 6.85 ± 0.34          | 5.45 ± 0.31          | 4.7 ± 0.28           | 0.000*  |
| Third week after treatment| 4.98 ± 0.35    | 6.3 ± 0.33           | 4.75 ± 0.34          | 3.9 ± 0.25           | 0.000*  |
| Sixth week after treatment| 4.35 ± 0.38    | 6.18 ± 0.35          | 4.1 ± 0.33           | 2.78 ± 0.25          | 0.000*  |

A: Placebo, B: *Thymus daenensis* group, C: Diclofenac group *P < 0.05.

Fig. 7 - Comparison of knee osteoarthritis patients with respect to physical performance in the 3 groups during 6 intervals of follow-up. A: placebo group, B: *Thymus daenensis* group, C: diclofenac group.

Fig. 8 - Comparison of knee osteoarthritis patients with respect to pain rate in the 3 groups during 6 intervals of follow-up based on VAS criterion. A: Placebo group, B: *Thymus daenensis* group, C: Diclofenac group.

difference than diclofenac group up to fifth interval or third week after intervention. This result may be due to the characteristics of the compounds in the extract of this plant. For example, there is flavonoid compound in this extract and various studies such as the study conducted by Asgari et al. have shown that these compounds can reduce the production of arachidonic acid through Inhibition of cyclooxygenase and lipoxygenase [46]. Substances resulting from the oxidation of arachidonic acid cause pain and
inflammation in the tissue [51], which in turn will intensify the pain. As a result, flavonoids reduce the pain and inflammation. Research has also proven that these compounds can act as ligands for opioid receptors and directly exert their analgesic effect [52]. Since the effects of oxidative stress and the products of oxidative reactions on the creation of osteoarthritis have been proven, antioxidant effects of this plant can be possible causes of the observed effects, especially that effects of topical antioxidants containing vitamin C and E, selenium, zinc, isoflavones and polyphenols in tea in inhibiting oxidative stress processes in the skin have been demonstrated [53]. This suggests that topical application of antioxidants can also be effective. Free radicals of oxygen produced in the progression of this disease in joint, indirectly through causing tissue damage and direct effect on receptors causing pain, stimulate the neuroendocrine system [54].

The results obtained in the case of morning stiffness and stiffness of knee joint of patients during the day also indicated that there is Thymus daenensis gel reduces the stiffness of the knee joint that this reduction was equal to the fifth interval of follow-up with diclofenac. In the osteoarthritis disease, created inflammation leads to the creation of joint stiffness that our studied plant applies its anti-inflammatory effects through various mechanisms. The substances available in the plant extracts such as phenolic acids, alkaloids, tannins and saponins might be involved in this effect of thyme [20, 21, 55]. For example, in a study conducted by Cichocki et al. on the effect of several types of phenolic acids on mouse epidermal cells, it was observed that these compounds inhibited COX-2 activation. One of the most important enzymes that is involved in the production of inflammatory mediators such as prostaglandins, prostacyclin and thromboxane is cyclooxygenase whose inhibition inhibits the inflammatory pathways and loss of pain and inflammatory symptoms [56]. Another study by Singh et al. on cancerous cells confirmed the effect of isoquinoline alkaloid on the decreased expression of cyclooxygenase-2 and reduced production of prostaglandin E2 and prostaglandin E2 receptors [57]. In the case of physical performance of patients, physical activity significantly improved in both groups received diclofenac and Thymus daenensis that significant difference was not found between two groups to end of the study. This can be due to a reduction in knee pain of patients during daily activities and improvement in other symptoms of the disease by reducing inflammation.  

4.1. Limitations of study

Although the effectiveness of the thyme gel was approved in this study, there are some limitations to generalize these results to the entire population, including the small size of the population used in this study. Lack of objective criteria for estimating the performance of the patients, despite validity and reliability of WOMAC

| Table 8 − Comparison Means and 95% Confidence Intervals (CIs) of outcomes in osteoarthritis patients before and after treatment. |
| Outcomes | Groups | Initial | Final |
| --- | --- | --- | --- |
| | Mean ± SD | CI 95% | Mean ± SD | CI 95% |
| Knee Pain | A | 14.05 ± 4.75 | 12.53-15.56 | 10.35 ± 5.17 | 8.69-12.00 |
| | B | 15.05 ± 4.85 | 13.49-16.60 | 6.02 ± 3.87 | 4.78-7.25 |
| | C | 14.85 ± 5.06 | 13.23-16.46 | 3.57 ± 2.6 | 2.73-4.40 |
| Right Knee Pain | A | 2.85 ± 0.97 | 2.53-3.16 | 2.1 ± 1.12 | 1.74-2.45 |
| | B | 3.05 ± 1.11 | 2.69-3.40 | 1.25 ± 0.84 | 0.98-1.51 |
| | C | 2.87 ± 1.15 | 2.50-3.23 | 0.67 ± 0.57 | 0.48-0.85 |
| Left Knee Pain | A | 2.62 ± 1.05 | 2.28-2.95 | 2.03 ± 1.12 | 1.67-2.38 |
| | B | 2.9 ± 0.98 | 2.58-3.21 | 1.1 ± 0.77 | 0.85-1.34 |
| | C | 2.85 ± 0.94 | 2.54-3.15 | 0.59 ± 0.58 | 0.4-0.77 |
| Morning Stiffness | A | 2.88 ± 0.93 | 2.58-3.17 | 2.07 ± 1.09 | 1.72-2.41 |
| | B | 3.07 ± 0.85 | 2.79-3.34 | 1.3 ± 0.82 | 1.03-1.56 |
| | C | 3.12 ± 0.99 | 2.80-3.43 | 0.75 ± 0.54 | 0.57-0.92 |
| Daily Stiffness | A | 2.88 ± 0.93 | 2.58-3.17 | 2.1 ± 1.1 | 1.74-2.45 |
| | B | 3.03 ± 0.89 | 2.74-3.31 | 1.25 ± 0.77 | 1.00-1.49 |
| | C | 3.12 ± 0.99 | 2.80-3.43 | 0.75 ± 0.54 | 0.57-0.92 |
| Physical Performance | A | 49.57 ± 16.21 | 44.38-54.75 | 37.66 ± 18.67 | 31.68-44.63 |
| | B | 53.47 ± 16.08 | 48.32-58.61 | 20.85 ± 14.4 | 16.24-25.45 |
| | C | 53.12 ± 17.72 | 47.45-58.71 | 12.85 ± 9.2 | 9.9-15.7 |
| Pain Rate Based on VAS Criterion | A | 7.33 ± 2.08 | 6.66-7.99 | 6.05 ± 2.18 | 5.35-6.74 |
| | B | 7.78 ± 2.16 | 7.08-8.47 | 3.68 ± 2.3 | 2.94-4.41 |
| | C | 7.65 ± 2.05 | 6.99-8.30 | 2.18 ± 1.08 | 1.83-2.52 |
questionnaire was another important limitation of the study. In addition, since the osteoarthritis is a disease with chronic nature, the study of variables at an interval after the intervention could be a limitation of our study. With increasing the period of study, we can have a better estimate of the impact and acceptability and safety of the gel. In addition, it determines side effects and topical and general effects resulting from continuous using of the considered drug well.

5. Conclusion

Based on the results of this study, the medicinal plant thyme could effectively reduce knee pain, morning stiffness and daily stiffness in the knees and improve physical performance of patients. In our study, no side effect for this plant was reported, so it can be argued that its use can produce a satisfactory effect on patients with osteoarthritis due to its low cost, easy access, the plant's natively occurring in Iran and no problem caused by the consumption of chemical drugs. It is suggested that be done further studies with different doses of the plant to be conducted to find the dose that has the highest impact and lowest side effect.

Acknowledgements

This study was derived from the MD thesis written by Elena Khalesi and funded by Shahrekord University of Medical Sciences (grant no.: 2124). The authors of this study appreciate Medical Plants Research Center and Clinical Research Development Unit, kashani Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran and all participated in this study.

Authors’ contributions

ZLG and MD contributed to the design of the study. EK and MD contributed to the patient's enrollment and evaluation. ZLG prepared the formulation and to the standardization of the herbal preparation. AA analyzed the data. AA and ZLG contributed to interpretation of the results. SA drafted the initial version of the manuscript. All authors read and approved the final version of the manuscript.

Conflict of interest statement

The authors disclose no conflicts of interest.

Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.

REFERENCES

[1] Altman RD. The syndrome of osteoarthritis. J Rheumatol. 1997; 24: 766-7.

[2] Pereira D, Peleteiro B, Araujo J, Branco J, Santos R, Ramos R. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartil. 2011; 19: 1270-85.

[3] Picavet H, Hazes J. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis. 2003; 62: 644-50.

[4] Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Gannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998; 41: 778-99.

[5] Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull. World Health Organ. 2003; 81: 646-56.

[6] Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. American College of Rheumatology. 1995; 38: 1535-40.

[7] Gamble R, Wyeth-Ayerst J, Johnson EL, Searle WA, Beecham S. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000; 43: 1905-15.

[8] Ibrahim SA. Racial variations in the utilization of knee and hip joint replacement: an introduction and review of the most recent literature. Curr Orthop Pract. 2010; 21: 126-31.

[9] Parmet S, Lynn C, Glass RM. JAMA patient page. Osteoarthritis of the knee. Jama. 2003; 289: 1068.

[10] Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, et al. Do physicians treat symptomatic osteoarthritic patients properly? Results of the AMICA experience. Semin. Arthritis Rheum. 2005; 35: 38-42.

[11] Harirforoosh S, Ashgar W, Jamali F. Adverse effects of nonsteroidal anti-inflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2014; 16: 821-47.

[12] Soubrier M, Rosenbaum D, Tatar Z, Lahaye C, Dubost JJ, Mathieu S. Vascular effects of nonsteroidal anti-inflammatory drugs. Joint Bone Spine. 2013; 80: 358-62.

[13] Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des. 2006; 12: 971-5.

[14] Sale JE, Gignac M, Hawker G. How “bad” does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis. Arthritis Care Res. 2006; 55: 272-8.

[15] Herman CJ, Allen F, Hunt WC, Prasad A, Brady TJ. Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis. 2004; 1: A12.

[16] Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med. 1999; 131: 409-16.

[17] Hashempur MH, Heydari M, Mosavat SH, Heydari ST, Shams M. Complementary and alternative medicine use in Iranian patients with diabetes mellitus. J Integr Med. 2015; 3: 319-25.

[18] Roozbeh J, Hashempur MH, Heydari M. Use of herbal remedies among patients undergoing hemodialysis. Iran J Kidney Dis. 2013; 7: 492-5.

[19] Morales R, Stahl Biskup E, Sáez F. The history, botany and taxonomy of the genus Thymus. Thyme: the genus Thymus. 2002: 1-43.

[20] Piccaglia R, Marotti M. Composition of the essential oil of an Italian Thymus vulgaris L. ecotype. Flavour Fragr J. 1991; 6: 241-4.

[21] Alizadeh A, Alizadeh O, Amari G, Zare M. Essential oil composition, total phenoliccontent, antioxidant activity and antifungal
properties of Iranian Thymus daenensis subsp. daenensis Celak. as in influenced by ontogenetical variation. J ESSENT OIL BEAR PL. 2013; 16: 59-70.

[22] Fazeli MR, Amin G, Attari MMA, Ashthani H, Jamalifar H, Samadi N. Antimicrobial activities of Iranian sumac and avishan-e shirazi (Zatania multiforma) against some food-borne bacteria. Food control. 2007; 18: 646-9.

[23] Pirbalouti AG, Hashemi M, Ghahfarokhi FT. Essential oil and chemical compositions of wild and cultivated Thymus daenensis Celak and Thymus vulgaris L. Ind Crops Prod. 2013; 48: 43-8.

[24] Fazeli MR, Amin G, Attari MMA, Ashtiani H, Jamalifar H, Samadi S. Antimicrobial activity of ethanolic extracts of some Iranian medicinal plants used by Bakhtiari tribal in Southwest Iran. Int J Biol. 2010; 2: 55-63.

[25] Pirbalouti AG, Malekpour F, Enteshari S, Yousefi M, Montaz H, Hamedi B. Antimicrobial activity of some folklore medicinal plants used by Bakhtiari tribal in Southwest Iran. Int J Biol. 2010; 2: 55-63.

[26] Shariatnia F, Ignacimuthu S. Antibacterial activity of some folklore medicinal plants (Lamiaceae). Food Control. 2013; 31: 218-23.

[27] Hamedi B. Antibacterial activity of some folklore medicinal plants used by Bakhtiari tribal in Southwest Iran. Int J Biol. 2010; 2: 55-63.

[28] Shahin F. Bioactivity of medicinal plant extracts against Listeria monocytogenes isolated from food. J Food Agric Environ. 2009; 7: 519-24.

[29] Hosseinzadeh H, Ramezani M, Salmani GA. Antinociceptive, anti-inflammatory and acute toxicity effects of Zataria multiflora Boiss extracts in mice and rats. J Ethnopharmacol. 2000; 73: 379-85.

[30] Asgari A, Parvin N. The Analgesic Effect of Ethanolic Extract of Tanacetum Parthenium in Acetic Acid Model. Zahedan J Res Med Sci. 2013; 15: 22-5.

[31] Amirghofran Z, Ahmadi H, Karimi MH. Immunomodulatory activity of the water extract of Thymus vulgaris, Thymus daenensis, and Zataria multiflora on dendritic cells and T cells responses. J Immunassay Immunochem. 2012; 33: 388-402.

[32] Ceylan R, Zengin G, Uysal S, Ilhan V, Aktunsek A, Kandenir A, et al. GC-MS analysis and in vitro antioxidant and enzyme inhibitory activities of essential oil from aerial parts of endemic Thymus spathulifolius Hausskn. et Velen. J Enzyme Inhib Med Chem. 2016; 31: 983-90.

[33] Kaur C, KapoorHC. Anti-oxidant activity and total phenolic content of some Asian vegetables. Int J Food Sci Technol. 2002; 37: 153-61.

[34] Liang T, Yue W, Li Q. Comparison of the phenolic content and antioxidant activities of Apocynum venetum L. (Luo-Bu-Ma) and two of its alternative species. Int J Mol Sci. 2010; 11: 4452-64.

[35] Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol. 1984; 2: 335-57.

[36] Katavic PL, Lamb K, Navarro H, Prisinzano TE. Flavonoids as Opioid Receptor Ligands: Identification and Preliminary Structure−Activity Relationships. J Nat Prod. 2007; 70: 1278-82.

[37] Pinnell SR. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol. 2003; 48: 1-22.
Oxidative stress in secondary osteoarthritis: from cartilage destruction to clinical presentation? Orthop Rev (Pavia). 2010; 2: e23.

[55] Meriçli FI, Tanker M. The Volatile Oils of Some Endemic Thymus Species Growing in Southern Anatolia1. Planta Med. 1986; 52: 340.

[56] Cichocki M, Blumczyńska J, Baer-Dubowska W. Naturally occurring phenolic acids inhibit 12-O-tetradecanoylphorbol-13-acetate induced NF-κB, iNOS and COX-2 activation in mouse epidermis. Toxicology. 2010; 268: 118-24.

[57] Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors. Carcinogenesis. 2011; 32: 86-92.